152 related articles for article (PubMed ID: 29058816)
1. Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.
Hsyu PH; Pignataro DS; Matschke K
Clin Pharmacol Drug Dev; 2018 May; 7(4):373-381. PubMed ID: 29058816
[TBL] [Abstract][Full Text] [Related]
2. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
[TBL] [Abstract][Full Text] [Related]
3. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
[TBL] [Abstract][Full Text] [Related]
4. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
5. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.
Abbas R; Leister C; Sonnichsen D
Clin Drug Investig; 2013 Aug; 33(8):589-95. PubMed ID: 23839484
[TBL] [Abstract][Full Text] [Related]
6. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
[TBL] [Abstract][Full Text] [Related]
7. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.
Abbas R; Boni J; Sonnichsen D
Drug Metab Pers Ther; 2015 Mar; 30(1):57-63. PubMed ID: 25803093
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
Abbas R; Chalon S; Leister C; El Gaaloul M; Sonnichsen D
Cancer Chemother Pharmacol; 2013 Jan; 71(1):123-32. PubMed ID: 23053269
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic and pharmacodynamic analysis of bosutinib.
Hsyu PH; Mould DR; Abbas R; Amantea M
Drug Metab Pharmacokinet; 2014; 29(6):441-8. PubMed ID: 24919837
[TBL] [Abstract][Full Text] [Related]
10. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
Abbas R; Hug BA; Leister C; Sonnichsen D
Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.
Hsyu PH; Mould DR; Upton RN; Amantea M
Cancer Chemother Pharmacol; 2013 Jan; 71(1):209-18. PubMed ID: 23070145
[TBL] [Abstract][Full Text] [Related]
12. Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):57-63. PubMed ID: 27717999
[TBL] [Abstract][Full Text] [Related]
13. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
14. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
Keller-V Amsberg G; Brümmendorf TH
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1121-7. PubMed ID: 23098112
[TBL] [Abstract][Full Text] [Related]
15. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
[TBL] [Abstract][Full Text] [Related]
17. The safety of Bosutinib for the treatment of chronic myeloid leukemia.
Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
[TBL] [Abstract][Full Text] [Related]
19. Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371.
Cho YS; Lim HS; Han S; Yoon SK; Kim H; Cho YL; Nam HS; Bae KS
Clin Ther; 2019 Jan; 41(1):92-106. PubMed ID: 30559004
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.
Hino M; Matsumura I; Fujisawa S; Ishizawa K; Ono T; Sakaida E; Sekiguchi N; Tanetsugu Y; Fukuhara K; Ohkura M; Koide Y; Takahashi N
Int J Hematol; 2020 Jul; 112(1):24-32. PubMed ID: 32279228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
